The company reaffirmed its FY24 guidance for product revenues, net, adjusted operating expenses and adjusted EBITDA for its current business, not including the impact of the planned acquisition of Ironshore. Collegium expects to update guidance to include Ironshore after closing of the acquisition.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COLL:
- COLL Earnings this Week: How Will it Perform?
- Affirm, Sprouts Farmers upgraded: Wall Street’s top analyst calls
- Collegium Pharmaceutical upgraded to Buy from Neutral at H.C. Wainwright
- Collegium Pharmaceutical’s Merger, Loan, and Board Reshuffle
- Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology